NITINOL BUSINESS acquired by RESONETICS
Context
The takeover of the SAES Getters Nitinol business by Resonetics establishes a rare, end-to-end metallurgical capability within the medical CDMO landscape. By absorbing the complete production chain—from the furnace to the finished catheter component—the organization bypasses the traditional constraints of specialized material procurement. This strategic consolidation addresses a critical bottleneck in the interventional device market, where high-grade Nitinol supply often dictates project timelines. Beyond simple supply chain security, the integration enables a deeper level of innovation; the group can now customize alloy chemistry to optimize the mechanical response of next-generation stents and heart valves. This move effectively insulates the platform from upstream price volatility and technical dependencies on external metal suppliers. By merging raw alloy science with precision laser-cutting expertise, the group offers a unique, high-security value proposition to global medtech OEMs.
NITINOL BUSINESS, which reported an EBITDA margin of [members only] in 2023, is valued in this transaction at an EV/EBITDA multiple of 15x–25x, representing a premium to the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
The Nitinol Business (Memry & SAES Smart Materials) is a United States organization specialized in Nitinol Medical Components. The entity operates as a technologically advanced leader in the development and manufacturing of next-generation, highly engineered medical components utilizing Nitinol shape memory alloys. At the heart of their operations is a philosophy of vertical integration, maintaining total control over the production process from the initial melting of the alloy to the final precision fabrication of medical components. They differentiate themselves through their mastery of super-elasticity and shape memory properties, which are essential for minimally invasive medical devices and life science applications.
Ent. Value
$500M–1.5bn
Equity Value
[members only]
Multiples
EV / Revenue
4x–10x
EV / EBITDA
15x–25x
EV / EBIT
[members only]
Historical Financials (USD)
Similar deals in Life Sciences
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 11/2023 | AMETEK | PARAGON MEDICAL | UNITED STATES | Medical Devices |
| 11/2023 | PARAGON | PRIMED | GERMANY | Medical Consumables |
| 10/2023 | LUXEMPART | ALPHACAPS | GERMANY | Nutrition & Dietary Supplements |
| 08/2023 | CARL ZEISS MEDITEC | D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) | NETHERLANDS | Medical Devices |
| 08/2023 | OAKLEY CAPITAL INVESTMENTS | LIBERTY DENTAL GROUP | GERMANY | Implants & Prosthetics |
| 08/2023 | ATHOS CONSORTIUM | SCHÜLKE | GERMANY | Medical Consumables |
| 07/2023 | LAUXERA | ORGANOX | UNITED KINGDOM | Medical Devices |
| 07/2023 | ELOS MEDTECH | KLINGEL MEDICAL GROUP | GERMANY | Implants & Prosthetics |
| 07/2023 | EQT PARTNERS / ADIA | DECHRA PHARMACEUTICALS | UNITED KINGDOM | Pharma & Biotech |
| 06/2023 | NOVO NORDISK | BIOCORP | FRANCE | Medical Devices |
Other operations with RESONETICS
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 03/2026 | RESONETICS | RESOLUTION MEDICAL | UNITED STATES | Medical Devices |
| 12/2021 | THE CARLYLE GROUP / GTCR | RESONETICS | UNITED STATES | Medical Devices |
REFERENCES
Valuation range: EV $500M–1.5bn
Revenue range: $100–200M
EBITDA range: $50–100M
EV/Revenue range: 4x - 10x
EV/EBITDA range: 15x - 25x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NITINOL BUSINESS by RESONETICS are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Acquirer: resonetics